Safety and Tolerability of GTX-104 Compared With Oral Nimodipine in Patients With aSAH
Phase 3
Active, not recruiting
- Conditions
- Aneurysmal Subarachnoid Hemorrhage (aSAH)
- Interventions
- Drug: Nimotop 30 MG Oral CapsuleDrug: GTX-104
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05995405
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Brain and Spine Neurological Institute, Phoenix, Arizona, United States
🇺🇸Community Regional Medical Center, Fresno, California, United States
Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects
Phase 1
- Conditions
- Ataxia Telangiectasia
- Interventions
- Drug: GTX-102 high dose fast Period 1 and Period 2Drug: GTX-102 medium dose fast Period 1 and Period 2Drug: Betamethasone Oral Solution Period 1 and Period 2Drug: Betamethasone solution as intramuscular injection Period 1 and Period 2Drug: GTX-102 low dose fast Period 1 and Period 2Drug: GTX-102 medium dose slow Period 1 and Period 2
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05531890
- Locations
- 🇨🇦
Clinical Research Unit, Toronto, Ontario, Canada
Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects
Phase 1
- Conditions
- Postherpetic Neuralgia
- Interventions
- Drug: Bupivacaine HCl subcutaneous injectionDrug: GTX-101
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05517486
- Locations
- 🇨🇦
Clinical Research Unit, Montréal, Canada
Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
Phase 1
Completed
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Drug: Nimodipine CapsulesDrug: GTX-104
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05418348
- Locations
- 🇨🇦
Clinical Research Unit, Montréal, Canada
A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
Phase 3
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: PlaceboDrug: CaPre
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 256
- Registration Number
- NCT03398005
- Locations
- 🇺🇸
Research site, Kenosha, Wisconsin, United States
A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
Phase 3
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: CaPreDrug: Placebo
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT03361501
- Locations
- 🇲🇽
Research site, Mexico City, Mexico
Assess the Safety and Efficacy of NKPL66 (CaPreâ„¢) in the Treatment of Mild-to-high Hypertriglyceridemia
Phase 2
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Dietary Supplement: CaPreâ„¢Drug: Lipid Lowering Medication
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 289
- Registration Number
- NCT01516151
- Locations
- 🇨🇦
CSSS Vallee De L'Or, Val d'Or, Quebec, Canada
🇨🇦BC Diabetes, Vancouver, British Columbia, Canada
🇨🇦Entralogix Clinical Research, Toronto, Ontario, Canada
TRIal For Efficacy of Capre on hyperTriglyceridemiA
Phase 2
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: CaPre (TM)Other: Placebo
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 387
- Registration Number
- NCT01455844
- Locations
- 🇨🇦
Centre médical-des-carrières, St-Marc-des-carrières, Quebec, Canada
🇨🇦Robarts Research Institute, London, Ontario, Canada
🇨🇦SPARC, Siebens-Drake Research Institute, London, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath